Cargando…
Biomarkers in immunotherapy: literature review and future directions
Within the past decade, immunotherapy has revolutionized the treatment of advanced non-small lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) such as pembrolizumab, nivolumab, atezolizumab, and durvalumab have shown superiority over chemotherapy regimens in patients with programmed death-lig...
Autores principales: | Pharaon, Rebecca, Koczywas, Maria A., Salgia, Sabrina, Mohanty, Atish, Massarelli, Erminia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578474/ https://www.ncbi.nlm.nih.gov/pubmed/33145089 http://dx.doi.org/10.21037/jtd.2020.04.15 |
Ejemplares similares
-
Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
por: Amanam, Idoroenyi, et al.
Publicado: (2020) -
Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence
por: Pharaon, Rebecca, et al.
Publicado: (2020) -
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer
por: Roosan, Moom R., et al.
Publicado: (2021) -
Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020) -
Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression
por: Reyes, Amanda, et al.
Publicado: (2022)